Neurofibromatosis Type 1 clinical trials

Explore recruiting neurofibromatosis type 1 clinical trials.

Recruiting neurofibromatosis type 1 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neurofibromatosis Type 1 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Trametinib in neurofibromatosis type 1 related symptomatic plexiform neurofibromas

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib after Multiple Doses in Adolescent Children with Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1B, Open-Label Study of Mirdametinib in Infants and Toddlers with Neurofibromatosis Type 1 associated Plexiform Neurofibromas

Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥ 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE).

Germany, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III, Multicentre, International Study with a Parallel, Randomised, Double blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiforn Neurofibromas (KOMET)

Germany, Spain, France, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neurofibromatosis Type 1 trials by city

Neurofibromatosis Type 1 in Toronto Neurofibromatosis Type 1 in Vancouver Neurofibromatosis Type 1 in Montreal Neurofibromatosis Type 1 in Calgary Neurofibromatosis Type 1 in Edmonton Neurofibromatosis Type 1 in Ottawa Neurofibromatosis Type 1 in Winnipeg Neurofibromatosis Type 1 in Quebec City Neurofibromatosis Type 1 in Hamilton Neurofibromatosis Type 1 in Kitchener Neurofibromatosis Type 1 in London Neurofibromatosis Type 1 in Halifax Neurofibromatosis Type 1 in New York Neurofibromatosis Type 1 in Los Angeles Neurofibromatosis Type 1 in Chicago Neurofibromatosis Type 1 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease